THE ANNUAL BLOOD BRAIN BARRIER CONSORTIUM MEETING

第六届血脑屏障协会年会定于2000年4月27日至29日在香港政府营Timberline Lodge举行。来自血脑屏障(BBB)联盟参与机构的主要研究人员、临床工作人员和研究人员已被邀请参加，以及来自其他大学的临床医生和研究人员对评估剂量强度在化疗敏感性脑瘤中的重要性感兴趣。这次正在进行的年度会议提出了这样的假设，即增加治疗药物在中枢神经系统恶性肿瘤中的应用可以改善存活率和生活质量，而不会产生不必要的毒性。年会的目标是回顾临床前研究进展，讨论临床结果和问题，并制定新的临床研究方案。此外，与以前的BBB联合会会议一样，这次会议将聚焦于肿瘤学或生物学中可能影响脑肿瘤治疗的研究进展的一两个领域。2000年会议的主题是“剂量强度”，将讨论两个主要领域。(1)实施一项国际第二阶段研究，使用两个同时进行的方案，比较血脑屏障破坏化疗和大剂量静脉注射。用于治疗原发中枢神经系统淋巴瘤的化疗，以及(2)两臂临床研究的潜在发展，以评估剂量强度在化疗敏感性少突胶质瘤中的作用。这次年度会议将为从事脑瘤治疗领域的研究人员提供一个论坛，让他们与来自美国各地的研究人员见面，了解血脑屏障计划和其他新的临床方法，将临床前研究转化为临床，并制定方案，以确定对化疗敏感的脑肿瘤的最佳治疗策略。

The sixth Annual Blood-Brain Barrier Consortium Meeting is scheduled for April 27-29, 2000, at Timberline Lodge, Government Camp OR. Principle investigators, clinical staff, and researchers from the participating institutions of the Blood-Brain Barrier (BBB) Consortium have been invited to attend, as well as clinicians and researchers from other universities interested in assessing the importance of dose intensity in chemosensitive brain tumors. This ongoing annual meeting addresses the hypothesis that increased delivery of therapeutics in CNS malignancy can improve survival and quality of life without undue toxicity. The goals of the annual meeting are to review preclinical research advances, discuss clinical results and problems, and develop new clinical research protocols. Additionally, as at previous BBB Consortium meetings, this meeting will spotlight one or two areas of oncology or biology in which research advances may be impact brain tumor therapy. The topic of the 2000 meeting will be dose intensity", and two major areas will be discussed. (1) implementation of an international phase II study using two concurrent protocols comparing blood-brain barrier disruption chemotherapy with high-dose i.v. chemotherapy for the treatment of primary CNS lymphoma, and (2) potential development of a two-arm clinical study to assess the role of dose intensity in chemotherapy sensitive oligodendroglioma. This annual meeting will provide a forum for investigators working in the area of brain tumor therapy to meet fellow researchers from across the United States, learn about the Blood- Brain Barrier program and other new clinical approaches, translate preclinical research to the clinic, and develop protocols to determine optimal treatment strategies for chemo-sensitive brain tumors.